{"id":40525,"date":"2025-04-07T10:37:55","date_gmt":"2025-04-07T08:37:55","guid":{"rendered":"https:\/\/www.vismederiholding.com\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/"},"modified":"2025-04-07T10:38:49","modified_gmt":"2025-04-07T08:38:49","slug":"new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine","status":"publish","type":"post","link":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/","title":{"rendered":"Nuova pubblicazione: Studio di Fase II\/III su un vaccino booster contro SARS-CoV-2"},"content":{"rendered":"<p class=\"\" data-start=\"1157\" data-end=\"1448\"><strong data-start=\"1157\" data-end=\"1179\">Emanuele Montomoli<\/strong> (CSO e Fondatore) e <strong data-start=\"1200\" data-end=\"1222\">Alessandro Manenti<\/strong> (CDO) sono co-autori di una nuova pubblicazione scientifica riguardante uno <strong data-start=\"1299\" data-end=\"1332\">studio clinico di Fase II\/III<\/strong> volto a valutare <strong data-start=\"1350\" data-end=\"1395\">immunogenicit\u00e0, sicurezza e tollerabilit\u00e0<\/strong> di un nuovo <strong data-start=\"1408\" data-end=\"1445\">vaccino booster contro SARS-CoV-2<\/strong>.<\/p>\n<p class=\"\" data-start=\"1450\" data-end=\"1663\">Lo studio nasce da una significativa collaborazione internazionale tra <strong data-start=\"1521\" data-end=\"1534\">VisMederi<\/strong> e vari partner argentini, tra cui l\u2019<strong data-start=\"1571\" data-end=\"1619\">Instituto de Investigaciones Biotecnol\u00f3gicas<\/strong> e l\u2019<strong data-start=\"1624\" data-end=\"1662\">Universidad Nacional de San Mart\u00edn<\/strong>.<\/p>\n<p class=\"\" data-start=\"1665\" data-end=\"1805\">\ud83d\udcc4 L\u2019articolo completo \u00e8 disponibile qui:<br data-start=\"1706\" data-end=\"1709\" \/>\ud83d\udd17 <a class=\"\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X25003421\" target=\"_new\" rel=\"noopener\" data-start=\"1712\" data-end=\"1805\">Leggi su ScienceDirect<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Emanuele Montomoli (CSO e Fondatore) e Alessandro Manenti (CDO) sono co-autori di una nuova pubblicazione scientifica riguardante uno studio clinico di Fase II\/III volto a valutare immunogenicit\u00e0, sicurezza e tollerabilit\u00e0 di un nuovo vaccino booster contro SARS-CoV-2. Lo studio nasce da una significativa collaborazione internazionale tra VisMederi e vari partner argentini, tra cui l\u2019Instituto de [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":40523,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[109],"tags":[116,157,170,165,185,128,159,160,187,135,151],"dipi_cpt_category":[],"class_list":["post-40525","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newseventi","tag-emanuele-montomoli-it","tag-immunization-it","tag-international-study-it","tag-research-it","tag-serological-testing-it","tag-siena-it","tag-vaccinations-it","tag-vaccine-it","tag-vaccine-assessment-it","tag-vaccine-development-it","tag-vismederi-group-it"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nuova pubblicazione: Studio di Fase II\/III su un vaccino booster contro SARS-CoV-2 - Vismederi Holding<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuova pubblicazione: Studio di Fase II\/III su un vaccino booster contro SARS-CoV-2 - Vismederi Holding\" \/>\n<meta property=\"og:description\" content=\"Emanuele Montomoli (CSO e Fondatore) e Alessandro Manenti (CDO) sono co-autori di una nuova pubblicazione scientifica riguardante uno studio clinico di Fase II\/III volto a valutare immunogenicit\u00e0, sicurezza e tollerabilit\u00e0 di un nuovo vaccino booster contro SARS-CoV-2. Lo studio nasce da una significativa collaborazione internazionale tra VisMederi e vari partner argentini, tra cui l\u2019Instituto de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Vismederi Holding\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T08:37:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-07T08:38:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/04\/Untitled-design.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Elec23\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elec23\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/\"},\"author\":{\"name\":\"Elec23\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#\\\/schema\\\/person\\\/2001c2c9d347ea0b6f36abac39396e9c\"},\"headline\":\"Nuova pubblicazione: Studio di Fase II\\\/III su un vaccino booster contro SARS-CoV-2\",\"datePublished\":\"2025-04-07T08:37:55+00:00\",\"dateModified\":\"2025-04-07T08:38:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/\"},\"wordCount\":89,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Untitled-design.png\",\"keywords\":[\"Emanuele Montomoli\",\"Immunization\",\"International Study\",\"research\",\"Serological Testing\",\"siena\",\"vaccinations\",\"vaccine\",\"Vaccine Assessment\",\"vaccine development\",\"vismederi group\"],\"articleSection\":[\"News&amp;eventi\"],\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/\",\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/\",\"name\":\"Nuova pubblicazione: Studio di Fase II\\\/III su un vaccino booster contro SARS-CoV-2 - Vismederi Holding\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Untitled-design.png\",\"datePublished\":\"2025-04-07T08:37:55+00:00\",\"dateModified\":\"2025-04-07T08:38:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#\\\/schema\\\/person\\\/2001c2c9d347ea0b6f36abac39396e9c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Untitled-design.png\",\"contentUrl\":\"https:\\\/\\\/www.vismederiholding.com\\\/vh\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Untitled-design.png\",\"width\":1080,\"height\":1350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuova pubblicazione: Studio di Fase II\\\/III su un vaccino booster contro SARS-CoV-2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#website\",\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/\",\"name\":\"Vismederi Holding\",\"description\":\"A group with expertise in the evaluation of vaccine immunogenicity\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/#\\\/schema\\\/person\\\/2001c2c9d347ea0b6f36abac39396e9c\",\"name\":\"Elec23\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g\",\"caption\":\"Elec23\"},\"url\":\"https:\\\/\\\/www.vismederiholding.com\\\/it\\\/author\\\/elec23\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuova pubblicazione: Studio di Fase II\/III su un vaccino booster contro SARS-CoV-2 - Vismederi Holding","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/","og_locale":"it_IT","og_type":"article","og_title":"Nuova pubblicazione: Studio di Fase II\/III su un vaccino booster contro SARS-CoV-2 - Vismederi Holding","og_description":"Emanuele Montomoli (CSO e Fondatore) e Alessandro Manenti (CDO) sono co-autori di una nuova pubblicazione scientifica riguardante uno studio clinico di Fase II\/III volto a valutare immunogenicit\u00e0, sicurezza e tollerabilit\u00e0 di un nuovo vaccino booster contro SARS-CoV-2. Lo studio nasce da una significativa collaborazione internazionale tra VisMederi e vari partner argentini, tra cui l\u2019Instituto de [&hellip;]","og_url":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/","og_site_name":"Vismederi Holding","article_published_time":"2025-04-07T08:37:55+00:00","article_modified_time":"2025-04-07T08:38:49+00:00","og_image":[{"width":1080,"height":1350,"url":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/04\/Untitled-design.png","type":"image\/png"}],"author":"Elec23","twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Elec23"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/#article","isPartOf":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/"},"author":{"name":"Elec23","@id":"https:\/\/www.vismederiholding.com\/it\/#\/schema\/person\/2001c2c9d347ea0b6f36abac39396e9c"},"headline":"Nuova pubblicazione: Studio di Fase II\/III su un vaccino booster contro SARS-CoV-2","datePublished":"2025-04-07T08:37:55+00:00","dateModified":"2025-04-07T08:38:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/"},"wordCount":89,"commentCount":0,"image":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/04\/Untitled-design.png","keywords":["Emanuele Montomoli","Immunization","International Study","research","Serological Testing","siena","vaccinations","vaccine","Vaccine Assessment","vaccine development","vismederi group"],"articleSection":["News&amp;eventi"],"inLanguage":"it-IT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/","url":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/","name":"Nuova pubblicazione: Studio di Fase II\/III su un vaccino booster contro SARS-CoV-2 - Vismederi Holding","isPartOf":{"@id":"https:\/\/www.vismederiholding.com\/it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/04\/Untitled-design.png","datePublished":"2025-04-07T08:37:55+00:00","dateModified":"2025-04-07T08:38:49+00:00","author":{"@id":"https:\/\/www.vismederiholding.com\/it\/#\/schema\/person\/2001c2c9d347ea0b6f36abac39396e9c"},"breadcrumb":{"@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/#primaryimage","url":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/04\/Untitled-design.png","contentUrl":"https:\/\/www.vismederiholding.com\/vh\/wp-content\/uploads\/2025\/04\/Untitled-design.png","width":1080,"height":1350},{"@type":"BreadcrumbList","@id":"https:\/\/www.vismederiholding.com\/it\/new-publication-phase-ii-iii-study-on-a-sars-cov-2-booster-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vismederiholding.com\/it\/"},{"@type":"ListItem","position":2,"name":"Nuova pubblicazione: Studio di Fase II\/III su un vaccino booster contro SARS-CoV-2"}]},{"@type":"WebSite","@id":"https:\/\/www.vismederiholding.com\/it\/#website","url":"https:\/\/www.vismederiholding.com\/it\/","name":"Vismederi Holding","description":"A group with expertise in the evaluation of vaccine immunogenicity","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vismederiholding.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Person","@id":"https:\/\/www.vismederiholding.com\/it\/#\/schema\/person\/2001c2c9d347ea0b6f36abac39396e9c","name":"Elec23","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b961e9d0441215ad52989b36cbb5451ab4201ca0349f0b53b1080b8b365531a3?s=96&d=mm&r=g","caption":"Elec23"},"url":"https:\/\/www.vismederiholding.com\/it\/author\/elec23\/"}]}},"_links":{"self":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts\/40525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/comments?post=40525"}],"version-history":[{"count":1,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts\/40525\/revisions"}],"predecessor-version":[{"id":40526,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/posts\/40525\/revisions\/40526"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/media\/40523"}],"wp:attachment":[{"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/media?parent=40525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/categories?post=40525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/tags?post=40525"},{"taxonomy":"dipi_cpt_category","embeddable":true,"href":"https:\/\/www.vismederiholding.com\/it\/wp-json\/wp\/v2\/dipi_cpt_category?post=40525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}